Fibromyalgia – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of fibromyalgia comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of fibromyalgia for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets covered in this report.

Clarivate Epidemiology’s fibromyalgia forecast will answer the following questions:

  • Of all people with fibromyalgia, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
  • Of all people diagnosed with fibromyalgia, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of fibromyalgia over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 13 fibromyalgia patient populations, as follows:

  • Total prevalent cases.
  • Total prevalent cases with anxiety.
  • Total prevalent cases without anxiety.
  • Total prevalent cases with depression.
  • Total prevalent cases without depression.
  • Total prevalent cases with migraine.
  • Total prevalent cases without migraine.
  • Total prevalent cases with insomnia.
  • Total prevalent cases without insomnia.
  • Diagnosed prevalent cases.
  • Diagnosed drug-treated prevalent cases.
  • Diagnosed non-drug-treated prevalent cases.
  • Undiagnosed prevalent cases.
  • … and more (details available on request).

Note: Coverage may vary by country.